Fennec Pharmaceuticals Inc.
FENCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeFennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. Valued at $364.7M, FENC is a small-cap name in its sector. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.
Market Cap
$364.7M
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
11.80
EPS (TTM)
$-0.29
EPS (Fwd)
$0.89
ROE
-52.7%
ROA
-5.9%
Cash
$40.2M
Total Debt
$0
Free CF
-$2.4M
52W Change
24.3%
Annual Financials
Cash vs Debt
Fennec Pharmaceuticals Inc. reports $40.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$2.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -52.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.5M (2022) to $44.6M (2025), reflecting a 2808% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fennec Pharmaceuticals Inc. and its sector.